Innospec Inc. (0JAX)
London Exchange · UK · prices in USD · close of 19 Oct 2026
Key indicators
| Last close | USD 98.09 |
|---|---|
| 52-week range | 65.23 – 111.31 |
| Return, 1 month / 3 months | +6.0% / +19.3% |
| Return, 1 year / 3 years | −10.9% / – |
| Trend | Uptrend |
| RSI (14) | 56 |
| Volatility (1 year) | 32.3% |
| Worst drawdown (1 year) | -26.3% |
| Average daily value traded | 0.00M USD |
| Dividend yield | 1.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Innospec Inc. is a specialty chemicals company that makes fuel additives and performance chemicals. Its fuel additives improve combustion and engine performance for refiners and fuel marketers, while its performance chemicals serve oilfield service firms, personal care formulators and industrial customers. The company also supplies ingredients used in fragrances and cosmetics. Innospec is based in the United States and serves customers in markets around the world.
Innospec Inc. trades under the code 0JAX on the London Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Innospec Inc. (0JAX) trades on the London Exchange in UK. It last closed at USD 98.09 on 19 October 2026.
Its price-based Market X-Ray is 67 out of 100 (a fair price profile), ranking 717 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 10.9% and over the last three months it rose 19.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 91 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | – | ||
| From 52-week high | -1.1% | ||
| Momentum | 90 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 19.3% | ||
| 6-month return | 39.1% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 57 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 32.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.3% | ||
| Liquidity | 7 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M USD | ||
| Zero-volume days | 6.7% | ||
| Income | 71 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 1.8% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Income: Dividend is high and has been paid regularly.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +2.3% |
|---|---|
| 1 month | +6.0% |
| 3 months | +19.3% |
| 6 months | +39.1% |
| 1 year | −10.9% |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 94.18 / 82.17 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.53 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 19 May 2026 | USD 0.9200 |
| 18 Nov 2025 | USD 0.8700 |
| 20 May 2025 | USD 0.8400 |
| 18 Nov 2024 | USD 0.7900 |
| 17 May 2024 | USD 0.7600 |
| 17 Nov 2023 | USD 0.7200 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.